https://scholars.lib.ntu.edu.tw/handle/123456789/590982
標題: | Nivolumab in previously treated advanced gastric cancer (ATTRACTION-2): 3-year update and outcome of treatment beyond progression with nivolumab | 作者: | Boku N. Satoh T. Ryu M.-H. Chao Y. Kato K. Chung H.C. Chen J.-S. Muro K. Kang W.K. KUN-HUEI YEH Yoshikawa T. Oh S.C. Bai L.-Y. Tamura T. Lee K.-W. Hamamoto Y. Kim J.G. Chin K. Oh D.-Y. Minashi K. Cho J.Y. Tsuda M. Nishiyama T. Chen L.-T. Kang Y.-K. |
關鍵字: | ATTRACTION-2; Gastric or gastroesophageal junction cancer; Long-term efficacy; Nivolumab; Treatment beyond progression | 公開日期: | 2021 | 出版社: | Springer Japan | 卷: | 24 | 期: | 4 | 起(迄)頁: | 946-958 | 來源出版物: | Gastric Cancer | 摘要: | Background: ATTRACTION-2 demonstrated that nivolumab improved overall survival (OS) vs placebo in patients with advanced gastric cancer treated with ? 2 chemotherapy regimens. However, its long-term efficacy and outcome of treatment beyond progression (TBP) with nivolumab have not been clarified. Methods: The 3-year follow-up data were collected. A subset analysis was performed to explore the efficacy of TBP by assessing postprogression survival (PPS) after the first event of disease progression. Results: Overall, 493 patients were randomized (2:1) to receive nivolumab (n = 330) or placebo (n = 163). With a median follow-up of 38.5 (range 36.1–47.5) months, OS of the nivolumab group was significantly longer compared to the placebo group (median 5.3 vs 4.1?months; 3-year survival rate, 5.6% vs 1.9%; hazard ratio [HR], 0.62 [95% confidence interval (CI) 0.50–0.75], P < 0.0001). The median OS of responders (n = 32) who achieved complete response or partial response was 26.7?months and the 3-year survival rate was 35.5% in the nivolumab group. Overall, 109 patients in the nivolumab group and 37 patients in the placebo group received TBP. PPS tended to be longer in the nivolumab group vs placebo group (median 5.8 vs 4.5?months; HR [95% CI], 0.69 [0.47–1.01], P = 0.057). In contrast, PPS was similar between both treatment groups in non-TBP patients (median 2.3 vs 2.2?months; HR 0.90, P = 0.42). Conclusions: Long-term efficacy of nivolumab was confirmed at the 3-year follow-up, and a survival benefit of TBP with nivolumab was suggested. Biomarkers for selecting patients suitable for TBP with nivolumab should be identified in the future. ? 2021, The Author(s). |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-85103182269&doi=10.1007%2fs10120-021-01173-w&partnerID=40&md5=aa3dad3147a36240f2de335fb427ac9f https://scholars.lib.ntu.edu.tw/handle/123456789/590982 |
ISSN: | 1436-3291 | DOI: | 10.1007/s10120-021-01173-w | SDG/關鍵字: | biological marker; nivolumab; placebo; immunological antineoplastic agent; nivolumab; acute hepatitis; adenocarcinoma; adult; Article; chemotherapy; colitis; computer assisted tomography; controlled study; disease exacerbation; double blind procedure; drug efficacy; drug safety; drug therapy; female; follow up; gene mutation; hazard ratio; histology; human; human tissue; hyperthyroidism; image analysis; maculopapular rash; major clinical study; male; microsatellite instability; middle aged; multiple cycle treatment; nuclear magnetic resonance imaging; phase 3 clinical trial; pneumonia; randomized controlled trial; solid malignant neoplasm; stomach cancer; survival rate; thyroiditis; toxicity; tumor cell; tumor volume; aged; clinical trial; mortality; stomach tumor; treatment outcome; Adult; Aged; Antineoplastic Agents, Immunological; Disease Progression; Double-Blind Method; Female; Follow-Up Studies; Humans; Male; Middle Aged; Nivolumab; Progression-Free Survival; Stomach Neoplasms; Survival Rate; Treatment Outcome |
顯示於: | 腫瘤醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。